Researchers found a higher concentration of a specific kind of DNA -- extrachromosomal or ecDNA -- in more aggressive and advanced cancers that could mark them as targets for future therapies. They found significantly higher amounts of ecDNA in tumors from previously treated patients, leading to the theory that ecDNA might give a survival advantage to those tumors.